Latest Breaking News On - Paradise system - Page 6 : comparemela.com
Renal Denervation Shows Worth in Resistant Hypertension
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
De onde vem o que eu como: irrigação usa quase metade de toda a água do Brasil para produzir alimentos
globo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globo.com Daily Mail and Mail on Sunday newspapers.
“In the end, this is how you describe us: Banshee, shrew, whore, and hooker Fishwife, bitch, slutty man-eater. Look, this is how you belittle us”
These lyrics from Mandopop star Tan Weiwei (Sitar Tan) are powerful in their own right, but they take on a new urgency in a year when China saw several especially brutal cases of violence against women in the national spotlight. Soon before Tan’s song hit the internet, screenwriter and activist Xianzi appeared at a court in Beijing to hold a powerful CCTV host, Zhu Jun, accountable for sexual harassment. Hundreds of Xianzi’s fans gathered in the cold outside the courthouse in solidarity.
(1)
PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ ReCor Medical, Inc. ( ReCor ), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise Ultrasound Renal Denervation System (the Paradise System ) demonstrated positive results in the RADIANCE-HTN TRIO ( TRIO ) study, and, separately, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with uncontrolled hypertension who are inadequately responsive to anti-hypertensive medications.
The RADIANCE-HTN TRIO trial evaluated the efficacy and safety of the Paradise System - a catheter-based system designed to denervate the renal nerves with ultrasound energy - to reduce blood pressure in hypertensive patients (n=136) wherein all subjects were placed on a single-pill combination-drug containing 3 anti-hypertension medications (a calcium-channel blocker, an angiotensin II-receptor blocker, and a diuretic). After confirmation of inadequate
Share this article
Share this article
PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ ReCor Medical, Inc. ( ReCor ), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise™ Ultrasound Renal Denervation System (the Paradise System ) demonstrated positive results in the RADIANCE-HTN TRIO ( TRIO ) study, and, separately, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with uncontrolled hypertension who are inadequately responsive to anti-hypertensive medications.
The RADIANCE-HTN TRIO trial evaluated the efficacy and safety of the Paradise System – a catheter-based system designed to denervate the renal nerves with ultrasound energy – to reduce blood pressure in hypertensive patients (n=136) wherein all subjects were placed on a single-pill combination-drug containing 3 anti-hypertension medications (a calcium-channel blocker, an angiotensin II-receptor blocker, and a d
vimarsana © 2020. All Rights Reserved.